Astronics Corporation Reports 2022 First Quarter Financial Results
Astronics Corporation (Nasdaq: ATRO) reports Q1 2022 sales of $116.2 million, up 10% year-over-year, with a pretax income of $5.0 million, recovering from an $11.8 million loss last year. Bookings surged to $175.6 million, a 46% increase, achieving a book-to-bill ratio of 1.51. Backlog reached a record $475.1 million. Despite strong demand, supply chain issues delayed approximately $15 million in revenue. The company maintains its revenue guidance of $550 million to $600 million for the year, with Q2 revenue expectations between $125 million and $135 million.
- Sales increased by 10% to $116.2 million over Q1 2021.
- Achieved a book-to-bill ratio of 1.51, indicating strong future demand.
- Record backlog of $475.1 million, up 14% from year-end 2021.
- Supply chain issues delayed $15 million in revenue.
- Net loss of $3.1 million compared to $11.9 million loss last year, indicating ongoing financial challenges.
-
Sales for the quarter were
, up$116.2 million 10% over prior-year period -
Pretax income was
, up from a loss of$5.0 million in the prior-year period$11.8 million -
Bookings totaled
, up$175.6 million 46% over prior-year period; Achieved book-to-bill ratio of 1.51 -
Backlog increased
14% from year end 2021 to a record ; Aerospace backlog reached a record$475.1 million $394.0 million
He continued, “However, our operating environment remains very challenging, especially with respect to our supply chain. Our sales were up
First Quarter Results
|
Three Months Ended |
||||||||||
($ in thousands) |
|
|
|
|
%
|
||||||
|
|
|
|
|
|
||||||
Sales |
$ |
116,176 |
|
|
$ |
105,857 |
|
|
9.7 |
% |
|
Loss from Operations |
$ |
(4,167 |
) |
|
$ |
(9,512 |
) |
|
56.2 |
% |
|
Operating Margin % |
|
(3.6 |
)% |
|
|
(9.0 |
)% |
|
|
||
|
$ |
(11,284 |
) |
|
$ |
— |
|
|
|
||
Net Loss |
$ |
(3,101 |
) |
|
$ |
(11,909 |
) |
|
74.0 |
% |
|
Net Loss % |
|
(2.7 |
)% |
|
|
(11.3 |
)% |
|
|
||
*Adjusted EBITDA |
$ |
(353 |
) |
|
$ |
(496 |
) |
|
28.8 |
% |
|
*Adjusted EBITDA Margin % |
|
(0.3 |
)% |
|
|
(0.5 |
)% |
|
|
*Adjusted EBITDA is a Non-GAAP Performance Measure. Please see the attached table for a reconciliation of adjusted EBITDA to GAAP net income. |
First Quarter 2022 Results (compared with the prior-year period, unless noted otherwise)
Consolidated sales were up
In 2021, the Company was awarded a grant of up to
Consolidated operating loss improved measurably over the prior-year period as higher volume reflecting improvements in the commercial aerospace industry and the benefit of the AMJP helped to offset higher costs for inventory and labor.
In
The effective income tax rate was
Consolidated net loss was
Consolidated adjusted EBITDA loss was
Sequentially, compared with the fourth quarter of 2021, while revenue remained consistent, net loss was
Bookings were
Aerospace Segment Review (refer to sales by market and segment data in accompanying tables)
Aerospace First Quarter 2022 Results (compared with the prior-year period, unless noted otherwise)
Aerospace segment sales increased
Military Aircraft sales decreased
Aerospace segment operating profit was
Aerospace bookings in the first quarter of 2022 were
Test Systems Segment Review (refer to sales by market and segment data in accompanying tables)
Test Systems First Quarter 2022 Results (compared with the prior-year period, unless noted otherwise)
Test Systems segment sales were
Test Systems operating loss was
Bookings for the Test Systems segment in the quarter were
Liquidity and Financing
Cash on hand was
On
Based on Astronics’ financial projections, the Company expects to be compliant with its financial covenants for the duration of the agreement.
2022 Outlook
Planned capital expenditures for 2022 are expected to be approximately
First Quarter 2022 Webcast and Conference Call
The Company will host a teleconference today at
The
About
Safe Harbor Statement
This news release contains forward-looking statements as defined by the Securities Exchange Act of 1934. One can identify these forward-looking statements by the use of the words “expect,” “anticipate,” “plan,” “may,” “will,” “estimate” or other similar expressions and include all statements with regard to the impact of COVID-19 on the Company and its future, reaching any revenue or Adjusted EBITDA margin expectations, being in compliance with credit agreement covenants, the recovery of the commercial aerospace and test systems markets, the opportunities to leverage capabilities in other markets and the outcome of demand streams or expectations of demand by customers and markets. Because such statements apply to future events, they are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated by the statements. Important factors that could cause actual results to differ materially from what may be stated here include the impact of the global outbreak of COVID-19 and governmental and other actions taken in response, trend in growth with passenger power and connectivity on airplanes, the state of the aerospace and defense industries, the market acceptance of newly developed products, internal production capabilities, the timing of orders received, the status of customer certification processes and delivery schedules, the demand for and market acceptance of new or existing aircraft which contain the Company’s products, the need for new and advanced test and simulation equipment, customer preferences and relationships, and other factors which are described in filings by
FINANCIAL TABLES FOLLOW
|
||||||||
CONSOLIDATED STATEMENT OF OPERATIONS DATA |
||||||||
(Unaudited, $ in thousands except per share data) |
||||||||
|
|
|||||||
Three Months Ended |
||||||||
|
|
|
|
|||||
Sales |
$ |
116,176 |
|
|
$ |
105,857 |
|
|
Cost of products sold |
|
96,243 |
|
|
|
91,584 |
|
|
Gross profit |
|
19,933 |
|
|
|
14,273 |
|
|
Gross margin |
|
17.2 |
% |
|
|
13.5 |
% |
|
|
|
|
|
|||||
Selling, general and administrative |
|
24,100 |
|
|
|
23,785 |
|
|
SG&A % of sales |
|
20.7 |
% |
|
|
22.5 |
% |
|
Loss from operations |
|
(4,167 |
) |
|
|
(9,512 |
) |
|
Operating margin |
|
(3.6 |
)% |
|
|
(9.0 |
)% |
|
|
|
|
|
|||||
Net gain on sale of business |
|
(11,284 |
) |
|
|
— |
|
|
Other expense, net of other income |
|
462 |
|
|
|
534 |
|
|
Interest expense, net |
|
1,631 |
|
|
|
1,758 |
|
|
Income (Loss) before tax |
|
5,024 |
|
|
|
(11,804 |
) |
|
Income tax expense |
|
8,125 |
|
|
|
105 |
|
|
Net loss |
$ |
(3,101 |
) |
|
$ |
(11,909 |
) |
|
Net loss % of sales |
|
(2.7 |
)% |
|
|
(11.3 |
)% |
|
|
|
|
|
|||||
|
|
|
|
|||||
*Basic loss per share: |
$ |
(0.10 |
) |
|
$ |
(0.39 |
) |
|
*Diluted loss per share: |
$ |
(0.10 |
) |
|
$ |
(0.39 |
) |
|
|
|
|
|
|||||
*Weighted average diluted shares outstanding (in thousands) |
|
31,933 |
|
|
|
30,903 |
|
|
|
|
|
|
|||||
Capital expenditures |
$ |
1,160 |
|
|
$ |
1,905 |
|
|
Depreciation and amortization |
|
7,088 |
|
|
|
7,453 |
|
|
||||||||
SEGMENT DATA |
||||||||
(Unaudited, $ in thousands) |
||||||||
|
|
|||||||
|
Three Months Ended |
|||||||
|
|
|
||||||
Sales |
|
|
||||||
Aerospace |
$ |
101,394 |
|
$ |
81,430 |
|
||
Less inter-segment |
|
— |
|
|
(14 |
) |
||
|
|
101,394 |
|
|
81,416 |
|
||
|
|
|
||||||
Test Systems |
|
14,798 |
|
|
24,745 |
|
||
Less inter-segment |
|
(16 |
) |
|
(304 |
) |
||
Total Test Systems |
|
14,782 |
|
|
24,441 |
|
||
Total consolidated sales |
|
116,176 |
|
|
105,857 |
|
||
|
|
|
||||||
Segment operating profit (loss) and margins |
|
|
||||||
Aerospace |
|
3,050 |
|
|
(5,563 |
) |
||
|
|
3.0 |
% |
|
(6.8 |
)% |
||
Test Systems |
|
(1,787 |
) |
|
1,189 |
|
||
|
|
(12.1 |
)% |
|
4.9 |
% |
||
Total segment operating profit (loss) |
|
1,263 |
|
|
(4,374 |
) |
||
|
|
|
||||||
Net gain on sale of business |
|
(11,284 |
) |
|
— |
|
||
Interest expense |
|
1,631 |
|
|
1,758 |
|
||
Corporate expenses and other |
|
5,892 |
|
|
5,672 |
|
||
Income (loss) before taxes |
$ |
5,024 |
|
$ |
(11,804 |
) |
Reconciliation to Non-GAAP Performance Measures
In addition to reporting net income, a
|
||||||||
RECONCILIATION OF NET INCOME TO ADJUSTED EBITDA |
||||||||
(Unaudited, $ in thousands) |
||||||||
|
|
|
|
|||||
Consolidated |
||||||||
|
Three Months Ended |
|||||||
|
|
|
|
|||||
Net loss |
$ |
(3,101 |
) |
|
$ |
(11,909 |
) |
|
Add back (deduct): |
|
|
|
|||||
Interest expense |
|
1,631 |
|
|
|
1,758 |
|
|
Income tax expense |
|
8,125 |
|
|
|
105 |
|
|
Depreciation and amortization expense |
|
7,088 |
|
|
|
7,453 |
|
|
Equity-based compensation expense |
|
2,101 |
|
|
|
2,097 |
|
|
Restructuring-related charges including severance |
|
84 |
|
|
|
— |
|
|
Non-cash accrued 401K contribution |
|
1,011 |
|
|
|
— |
|
|
AMJP grant benefit |
|
(6,008 |
) |
|
|
— |
|
|
Net gain on sale of business |
|
(11,284 |
) |
|
|
— |
|
|
Adjusted EBITDA |
$ |
(353 |
) |
|
$ |
(496 |
) |
|
|
|
|
|
|||||
Sales |
$ |
116,176 |
|
|
$ |
105,857 |
|
|
Adjusted EBITDA margin |
|
(0.3 |
)% |
|
|
(0.5 |
)% |
|
||||||||
CONSOLIDATED BALANCE SHEET DATA |
||||||||
($ in thousands) |
||||||||
|
(unaudited) |
|
|
|||||
|
|
|
|
|||||
ASSETS |
|
|
|
|||||
Cash and cash equivalents |
$ |
24,015 |
|
$ |
29,757 |
|||
Accounts receivable and uncompleted contracts |
|
117,495 |
|
|
|
107,439 |
|
|
Inventories |
|
166,088 |
|
|
|
157,576 |
|
|
Other current assets |
|
18,331 |
|
|
|
45,089 |
|
|
Property, plant and equipment, net |
|
93,028 |
|
|
|
95,236 |
|
|
Other long-term assets |
|
20,697 |
|
|
|
21,439 |
|
|
Intangible assets, net |
|
90,504 |
|
|
|
94,320 |
|
|
|
|
58,313 |
|
|
|
58,282 |
|
|
Total assets |
$ |
588,471 |
|
|
$ |
609,138 |
|
|
|
|
|
|
|||||
LIABILITIES AND SHAREHOLDERS' EQUITY |
|
|
|
|||||
Accounts payable and accrued expenses |
$ |
93,987 |
|
|
$ |
91,257 |
|
|
Customer advances and deferred revenue |
|
27,198 |
|
|
|
27,356 |
|
|
Long-term debt |
|
137,000 |
|
|
|
163,000 |
|
|
Other liabilities |
|
70,204 |
|
|
|
70,921 |
|
|
Shareholders' equity |
|
260,082 |
|
|
|
256,604 |
|
|
Total liabilities and shareholders' equity |
$ |
588,471 |
|
|
$ |
609,138 |
|
|
||||||||
CONSOLIDATED CASH FLOWS DATA |
||||||||
(Unaudited, $ in thousands) |
||||||||
|
|
|
|
|||||
|
Three Months Ended |
|||||||
(Unaudited, $ in thousands) |
|
|
|
|||||
Cash flows from operating activities: |
|
|
|
|||||
Net loss |
$ |
(3,101 |
) |
|
$ |
(11,909 |
) |
|
Adjustments to reconcile net loss to cash from operating activities: |
|
|
|
|||||
Depreciation and amortization |
|
7,088 |
|
|
|
7,453 |
|
|
Provisions for non-cash losses on inventory and receivables |
|
175 |
|
|
|
1,269 |
|
|
Equity-based compensation expense |
|
2,101 |
|
|
|
2,097 |
|
|
Non-cash accrued 401(k) contribution |
|
1,011 |
|
|
|
— |
|
|
Deferred tax benefit |
|
— |
|
|
|
(51 |
) |
|
Operating lease non-cash expense |
|
1,424 |
|
|
|
1,185 |
|
|
Net gain on sale of business, before taxes |
|
(11,284 |
) |
|
|
— |
|
|
Other |
|
513 |
|
|
|
1,315 |
|
|
Cash flows from changes in operating assets and liabilities: |
|
|
|
|||||
Accounts receivable |
|
(10,024 |
) |
|
|
(6,010 |
) |
|
Inventories |
|
(9,015 |
) |
|
|
430 |
|
|
Accounts payable |
|
8,625 |
|
|
|
(4,171 |
) |
|
Accrued expenses |
|
(1,380 |
) |
|
|
(685 |
) |
|
Other current assets and liabilities |
|
(363 |
) |
|
|
961 |
|
|
Customer advance payments and deferred revenue |
|
(113 |
) |
|
|
2,915 |
|
|
Income taxes |
|
16,492 |
|
|
|
(246 |
) |
|
Operating lease liabilities |
|
(1,724 |
) |
|
|
(1,307 |
) |
|
Supplemental retirement plan and other liabilities |
|
(109 |
) |
|
|
(109 |
) |
|
Cash flows from operating activities |
|
316 |
|
|
|
(6,863 |
) |
|
Cash flows from investing activities: |
|
|
|
|||||
Proceeds on sale of business |
|
21,961 |
|
|
|
— |
|
|
Capital expenditures |
|
(1,160 |
) |
|
|
(1,905 |
) |
|
Cash flows from investing activities |
|
20,801 |
|
|
|
(1,905 |
) |
|
Cash flows from financing activities: |
|
|
|
|||||
Proceeds from long-term debt |
|
17,925 |
|
|
|
— |
|
|
Principal payments on long-term debt |
|
(43,925 |
) |
|
|
— |
|
|
Stock award activity |
|
108 |
|
|
|
(52 |
) |
|
Finance lease principal payments |
|
(23 |
) |
|
|
(501 |
) |
|
Debt acquisition costs |
|
(771 |
) |
|
|
— |
|
|
Cash flows from financing activities |
|
(26,686 |
) |
|
|
(553 |
) |
|
Effect of exchange rates on cash |
|
(173 |
) |
|
|
(362 |
) |
|
Decrease in cash and cash equivalents |
|
(5,742 |
) |
|
|
(9,683 |
) |
|
Cash and cash equivalents at beginning of period |
|
29,757 |
|
|
|
40,412 |
|
|
Cash and cash equivalents at end of period |
$ |
24,015 |
|
|
$ |
30,729 |
|
|
||||||||||||||
SALES BY MARKET |
||||||||||||||
(Unaudited, $ in thousands) |
||||||||||||||
|
|
|
||||||||||||
|
Three Months Ended |
|
||||||||||||
|
|
|
% Change |
% of Sales |
||||||||||
Aerospace Segment |
|
|
|
|
||||||||||
|
$ |
64,089 |
$ |
38,208 |
67.7 |
% |
55.1 |
% |
||||||
Military |
|
14,976 |
|
|
20,982 |
|
(28.6 |
)% |
12.9 |
% |
||||
Business Jet |
|
15,867 |
|
|
14,028 |
|
13.1 |
% |
13.7 |
% |
||||
Other |
|
6,462 |
|
|
8,198 |
|
(21.2 |
)% |
5.6 |
% |
||||
Aerospace Total |
|
101,394 |
|
|
81,416 |
|
24.5 |
% |
87.3 |
% |
||||
|
|
|
|
|
||||||||||
Test Systems Segment |
|
14,782 |
|
|
24,441 |
|
(39.5 |
)% |
12.7 |
% |
||||
|
|
|
|
|
||||||||||
Total Sales |
$ |
116,176 |
|
$ |
105,857 |
|
9.7 |
% |
|
|||||
|
|
|
|
|||||||||||
SALES BY PRODUCT LINE |
||||||||||||||
(Unaudited, $ in thousands) |
||||||||||||||
|
|
|
||||||||||||
|
Three Months Ended |
|
||||||||||||
|
|
|
% Change |
% of Sales |
||||||||||
Aerospace Segment |
|
|
|
|
||||||||||
|
$ |
44,467 |
|
$ |
29,344 |
|
51.5 |
% |
38.3 |
% |
||||
Lighting & Safety |
|
29,211 |
|
|
27,100 |
|
7.8 |
% |
25.1 |
% |
||||
Avionics |
|
18,875 |
|
|
14,843 |
|
27.2 |
% |
16.2 |
% |
||||
Systems Certification |
|
1,002 |
|
|
878 |
|
14.1 |
% |
0.9 |
% |
||||
Structures |
|
1,377 |
|
|
1,053 |
|
30.8 |
% |
1.2 |
% |
||||
Other |
|
6,462 |
|
|
8,198 |
|
(21.2 |
)% |
5.6 |
% |
||||
Aerospace Total |
|
101,394 |
|
|
81,416 |
|
24.5 |
% |
87.3 |
% |
||||
|
|
|
|
|
||||||||||
Test Systems Segment |
|
14,782 |
|
|
24,441 |
|
(39.5 |
)% |
12.7 |
% |
||||
|
|
|
|
|
||||||||||
Total Sales |
$ |
116,176 |
|
$ |
105,857 |
|
9.7 |
% |
|
|
||||||||||||||||||||
ORDER AND BACKLOG TREND |
||||||||||||||||||||
(Unaudited, $ in thousands) |
||||||||||||||||||||
|
|
|
|
Trailing |
||||||||||||||||
|
Q2 2021 |
Q3 2021 |
Q4 2021 |
Q1 2022 |
Twelve Months |
|||||||||||||||
|
|
|
|
|
|
|||||||||||||||
Sales |
|
|
|
|
|
|||||||||||||||
Aerospace |
$ |
89,220 |
$ |
95,766 |
$ |
98,836 |
$ |
101,394 |
$ |
385,216 |
||||||||||
Test Systems |
|
21,938 |
|
|
16,075 |
|
|
17,216 |
|
|
14,782 |
|
|
70,011 |
|
|||||
Total Sales |
$ |
111,158 |
|
$ |
111,841 |
|
$ |
116,052 |
|
$ |
116,176 |
|
$ |
455,227 |
|
|||||
|
|
|
|
|
|
|||||||||||||||
Bookings |
|
|
|
|
|
|||||||||||||||
Aerospace |
$ |
118,155 |
|
$ |
142,484 |
|
$ |
147,689 |
|
$ |
160,778 |
|
$ |
569,106 |
|
|||||
Test Systems |
|
8,166 |
|
|
11,052 |
|
|
29,651 |
|
|
14,844 |
|
|
63,713 |
|
|||||
Total Bookings |
$ |
126,321 |
|
$ |
153,536 |
|
$ |
177,340 |
|
$ |
175,622 |
|
$ |
632,819 |
|
|||||
|
|
|
|
|
|
|||||||||||||||
Backlog |
|
|
|
|
|
|||||||||||||||
Aerospace |
$ |
239,088 |
|
$ |
285,806 |
|
$ |
334,659 |
|
$ |
394,043 |
|
|
|||||||
Test Systems |
|
73,621 |
|
|
68,598 |
|
|
81,033 |
|
|
81,095 |
|
|
|||||||
Total Backlog |
$ |
312,709 |
|
$ |
354,404 |
|
$ |
415,692 |
|
$ |
475,138 |
|
|
N/A |
|
|||||
|
|
|
|
|
|
|||||||||||||||
Book:Bill Ratio |
|
|
|
|
|
|||||||||||||||
Aerospace |
|
1.32 |
|
|
1.49 |
|
|
1.49 |
|
|
1.59 |
|
|
1.48 |
|
|||||
Test Systems |
|
0.37 |
|
|
0.69 |
|
|
1.72 |
|
|
1.00 |
|
|
0.91 |
|
|||||
Total Book:Bill |
|
1.14 |
|
|
1.37 |
|
|
1.53 |
|
|
1.51 |
|
|
1.39 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20220506005067/en/
Company:
Phone: (716) 805-1599, ext. 159
Email: david.burney@astronics.com
Investor Relations:
Phone: (716) 843-3908
Email: dpawlowski@keiadvisors.com
Source:
FAQ
What were Astronics' sales for Q1 2022?
What is Astronics' revenue guidance for 2022?
What was the book-to-bill ratio for Astronics in Q1 2022?
How did supply chain issues impact Astronics' revenue?